The Role of Alcohol and Drug Relapse Prevention in the Treatment and Prevention of HIV DiseaseApril 1998 Although HIV disease and alcohol and drug abuse are distinct illnesses, each profoundly affects the other. Alcohol and drug abuse have been associated with high-risk sexual behavior such as unprotected sexual activity.(1-7) Although the data on whether alcohol or drug abuse can accelerate the progression of HIV infection to AIDS have conflicted,(8-10) some studies have supported such a relationship.(11-14) One recent study looked at the effects of HIV infection and chronic alcohol use on cerebral white matter concentrations of phosphodiester and phosphocreatine to determine adverse metabolic effects on the brain.(14) The study found that HIV infection and alcohol abuse were additive in their negative effects. Although more research is needed on the relationship between HIV disease progression and drug and alcohol abuse, it is worth asking whether addicts who are HIV-positive will be less compliant with medical treatment as a result of their substance abuse.
Concern for compliance has increased as a result of new complex combination- A separate study of compliance with ZDV therapy compared injection drug users (IDUs) with other HIV-positive subjects.(16) The study found that IDUs tended to delay longer than the others in starting the ZDV treatment after it had been proposed to them. However, once the IDUs accepted treatment, they demonstrated as much compliance as the other HIV-positive patients. As one would expect, among the IDUs those who had stopped taking street drugs altogether or took only their prescribed methadone were the most compliant compared with the still active (street) drug users. Good compliance overall may have been the result of the two most compliant subgroups making up most of the IDUs.(16) Whether complex combinations of antiviral medications are taken appropriately by alcohol and drug users is not known, but based on this study it is reasonable to speculate that alcohol or drug users who become abstinent will have superior compliance.
Every physician treating HIV disease would benefit from knowing some basic concepts of addiction medicine, just as every addictionologist needs to know about HIV. Depending on the geographic location, 5 to 60 percent of individuals acquiring HIV disease do so from injection drug use.(17) Injection drug use overall has grown to 37 percent as a likely cause of AIDS among adults in the United States.(18) Several studies have reported elevations in HIV risk behavior and infection among alcoholic inpatients,(19-22) although no studies to date tell us how many persons have acquired HIV disease while impaired from alcohol. Questions worth investigating further include: How many people continue to drink to excess and use drugs while HIV-positive? How does this contribute to the continual transmission of HIV disease? How does the use of drugs and alcohol affect the immune system and cause the disease to progress?
Addiction has been described as a chronic relapsing condition frequently requiring multiple attempts to quit before the addict is able to achieve a sober lifestyle. This may be a result of long-term, possibly irreversible, neurochemical changes that make the addicted brain qualitatively different from a nonaddicted brain. These differences are manifested by global declines in glucose metabolism and intraneuronal changes in gene expression and may explain susceptibility to relapse.(24)
An alternative but not mutually exclusive explanation looks at the addicted brain as having been differentially conditioned to environmental cues that produce cravings that frequently trigger lapses and eventual relapse. Marlatt and Gordon(25) proposed a social learning model of relapse that went beyond conditioning alone and emphasized the presence of high-risk situations, the recall of euphoric experiences, and the availability of coping skills.
Related to drug and alcohol relapse prevention training are approaches that target maintenance of safer sexual behaviors and safer drug injection behaviors such as needle exchange programs and bleach disinfection of needles. Such harm reduction programs attempt to encourage persons at risk to gradually reduce their harmful behaviors in a step-down approach to less dangerous forms, such as replacing heroin use with methadone maintenance.(26,27)
This article limits itself to drug and alcohol relapse prevention in the treatment and prevention of HIV disease. However, this is not meant to minimize the many different interventions available to limit HIV transmission and disease among alcohol and drug users, from harm reduction to treatments that successfully promote abstinence through extended follow-up.(28)
Modern medical and social learning explanations of chronic relapsing stand in sharp contrast to the moral approach, which earlier in the century viewed addicted persons as sinners with low moral fiber who lacked self-control over alcohol and drugs. The moral approach attempted to shame these sinners into sobriety with the help of religious conversion, but that approach has fallen into disfavor since the introduction of the disease model of alcoholism in the 1950s.
Marlatt and Gordon have recognized eight high-risk factors that can lead to relapse of alcohol and drug use (Table 1).(25) The goal of relapse prevention is for individuals to become aware of their own high-risk situations and to learn effective life- An alcoholic numbness or drug buzz is a simple and quick way for individuals to deal with feelings such as fear, shame, and despair brought on by HIV disease. However, when under the influence of alcohol or drugs, individuals are not in control of their lives or disease, which will in turn cause feelings of hopelessness. Learning to deal soberly with the different stages of HIV keeps individuals in control of their life and medical care. See Table 2 for a summary of the five components of relapse prevention.
Individuals are at risk for relapse at five stages in HIV disease progression. Each stage has its own challenges for the individual. Relapse prevention skills may help to reduce the risk of relapse that accompanies each stage.(29,30)
Many people are affected by HIV in some way, whether by knowing a celebrity, friend, or family member who has been diagnosed as HIV-positive or has AIDS or by simply making changes in their sexual behavior. Chemically dependent persons in particular have been at greater risk than the rest of the population and have suffered more as a result. This means that recovering persons need to become aware how they may be vulnerable to HIV and how even being tested for HIV can be a high-risk situation that can endanger their sobriety. Certainly, having to live with an HIV-positive diagnosis or developing AIDS- Individuals often are afraid to face their personal risks and use denial. They may continue to engage in unsafe sexual practices or avoid being tested because they do not believe that they or their partners are at risk of contracting HIV disease. Alcohol and drugs can aid their denial by allowing them to ignore knowledge of risk with an alcohol or drug fog.
Challenge: Responsibility vs harm.
Harm: John was a 35-year-old businessman who was a recovering prescription drug user. Since he dated only professional women, he never bothered with condoms. He believed, These women are too smart, too classy, to be HIV-positive. Only homosexuals get AIDS anyway. I am not in any risk.
Responsibility: John's sponsor confronted him with his self-destructive behavior. After John learned more about HIV disease and safer sex, he decided that he was at risk for becoming HIV-positive unless he changed his behavior. By taking better care of himself, he reduced his risks for relapse as well. He also learned that it is not possible to know whether a potential partner is HIV-positive based on appearance alone.
Coping plan to prevent relapse:
Individuals may know that they are at risk but refuse to be tested because they are afraid they might be positive and believe that they could not emotionally handle the test results, or they may falsely believe that after testing positive nothing can be done to maintain their health.
Challenge: Courage vs avoidance.
Avoidance: Marty was a 35-year-old recovering cocaine addict and gay man. He thought that being gay doomed him to be HIV-positive. When sober, he always practiced safer sex. However, when high on cocaine, he had often not been aware of who was with him or what he was doing. He was now feeling very depressed and hopeless about his probable HIV disease. As a result, he craved cocaine, hoping to lift his spirits.
Courage: Marty's sponsor told him that avoiding testing was putting him at risk for relapse. He agreed to be tested, and much to his surprise, the test was negative. Marty decided to remain this way by renewing his commitment to sobriety and safer sex.
Coping plan to prevent relapse:
Most physicians know patients who have tested positive but waited years before being evaluated and thus missed the benefits of early medical intervention. Individuals may be afraid to find out about their disease status.
Challenge: Taking charge vs denial.
Denial: Tom was a 50-year-old engineer and recovering alcoholic. He had probably become positive when he had a blood transfusion for a bleeding ulcer caused by his drinking. He learned that he was positive in his treatment program. At that time, he was advised to seek medical help but did not, thinking, What's the use? I am going to die anyway. He also disliked seeing doctors, whom he felt invaded his privacy by poking and prodding him. He felt he could handle the disease on his own. However, his denial was not allowing him to face his emotions honestly, and this put him in danger of relapse.
Taking charge: Tom's treatment counselor encouraged him to read about HIV disease and take charge of his life. Tom learned that being HIV-positive did not mean he had AIDS. He found a doctor he liked. The doctor explained to Tom that laboratory tests and a physical examination would help him devise a good medical care plan with which he could live. Tom discovered he had a high T-cell count and a low viral load and was physically in good shape. He began to feel in charge of his life again, and his relapse risk went down as a result.
Coping plan to prevent relapse:
A falling CD4+ count or rising viral load can cause fear about the unknown.
Challenge: Hope vs despair.
Despair: Mary's husband had been a hemophiliac who died of AIDS. She was HIV-positive as a consequence of sexual relations with him. Unable to cope with the loss of her husband, she had become an alcoholic. She did well physically and never thought much about being HIV-positive until she learned her CD4+ count was only 100/mm3. All of a sudden she became afraid and angry. She even started going to bars and having unprotected sex. She thought, Why not? If a man doesn't want to use condoms, he can get AIDS. I'm not going to live long anyway. Why not have fun?
Hope: Mary's therapist told her that she was acting out of anger and was risking her health, sobriety, and the well-being of others. She encouraged her to explore the anger in therapy instead and to see her physician. Mary went to her physician who prescribed medicine to prevent some likely diseases, such as Pneumocystis carinii pneumonia and Mycobacterium avium- Coping plan to prevent relapse:
Dealing with illness, possible disability, and death is hard for anyone.
Challenge: Self-determination vs loss of control.
Loss of control: Susan, a recovering prescription drug user, was a flight attendant. She contracted HIV from her former husband. As a single parent, she prided herself in working and taking care of her daughter without giving into her AIDS diagnosis. After having had P carinii pneumonia twice, she went back to work. She had even developed cytomegalovirus retinitis and worked while receiving intravenous treatment. However, the medicine was not helping and she was losing her sight. At work, she was told she had to take medical disability or lose her job. In desperation, she decided to go to her doctor and told him to stop everything. She now felt useless and out of control and thought, I am no longer of any use to anyone. She wanted to drown herself in pain medication and tranquilizers and die.
Self-determination: The doctor diagnosed Susan as clinically depressed. It was true that she could not hold her current job, but she could still do volunteer work and raise her child. He encouraged her to make plans in case she became terminal, such as determining who would care for her child, settling her financial matters, and writing a will. He encouraged her to look into experimental AIDS therapies and become involved with support groups. Susan did these things and started to feel that she was directing her own life again.
Coping plan to prevent relapse:
Patients have fears about HIV infection yet respond to fear in different ways. For example, by avoiding people, places, and situations that promote substance use, a recovering addict uses one important coping skill to deal with cravings. Similarly, by asking for support in dealing with the HIV testing process, the recovering addict helps prevent becoming emotionally isolated in facing a potentially overwhelming experience. An addict who lacks such skills is more likely to try to numb fears by using chemicals.
When they lack coping skills, patients often find that testing for HIV infection, waiting for the results, and getting the results can be overwhelming triggers for relapse. Sometimes patients who are afraid of testing say to themselves, What's the point? If I'm HIV-positive, I'll just die anyway. This is obviously self- Patients may find it embarrassing to admit that they have acted in ways that put them at high risk for HIV infection. Perhaps these behaviors involved unsafe sex, multiple sex partners, sex with prostitutes, or sharing needles. If they are prone to shame, they may see such behaviors as proof that they are basically worthless human beings. Such feelings can lead them to withdraw from other people so that no one will know about their behaviors.
There is another option. Patients can hang on to their self- Patients should try to take responsibility for actions that harmed others, to make amends, and to learn from their mistakes. At the same time, patients will need to always look at themselves with compassion. Admitting mistakes and making amends does not mean admitting to badness but rather that they, like all of us, are fallible human beings.
Patients avoid testing for a variety of reasons, especially when they falsely believe that finding out that they are HIV-positive is getting a death sentence or that even if they know their HIV status there is nothing they can do to prevent their getting AIDS. Patients may need help in overcoming such beliefs.
Physicians who treat HIV-positive patients will encounter psychiatric disorders and active substance abuse disorders in these patients at rates considerably higher than those in HIV-negative patients. One study at the John Hopkins Hospital General HIV Clinic found that 54 percent of consecutive patients seen suffered from a psychiatric disorder, while another 22 percent suffered from a chemical dependency problem.(34) Physicians can respond to these related disorders in a number of ways. They can use screening and referral procedures. They can read relevant literature.(29,34-37) They can attend conferences, such as those offered by the American Society of Addiction Medicine, to learn to identify chemical dependency problems as well as to provide brief interventions that enhance motivation in patients(35) or help prevent relapses that complicate HIV treatment. In general, physicians with the proper training should follow these recommendations:
Seventy-five percent of recovering individuals relapse in the first year.(39) Relapse prevention can reduce this number and therefore has a place in the care of the HIV-infected population. Individuals abstaining from drugs and alcohol may benefit from a stronger immune system and may be less likely to engage in unsafe sexual behavior that would allow them to contract sexually transmitted diseases or expose others to HIV disease.
It is hoped that more studies such as the ARRIVE program will be done to evaluate relapse prevention in the HIV-infected population. Additional questions that need to be resolved include what behavioral and cognitive skills are most useful for the person living with HIV; what stages of HIV disease are most likely to be greater relapse risks; and how relapse prevention material can be presented most effectively.
Individuals who are HIV-positive could benefit from assessment of drug and alcohol use, drug and alcohol detoxification, and training in relapse prevention skills. Relapse prevention is a tool that is available to physicians and can be applied in an outpatient medical setting. When this is not possible on site, brief intervention aimed at increasing motivation to get help and referral to chemical dependency practitioners are recommended.
1. Bagnall G, Plant M, Warwick W. Alcohol, drugs, and AIDS-related risks: results from a prospective study. AIDS Care 1990;2:309-317.
2. Stall R, McKusick L, Wiley J, Coates TJ, Ostrowe DG. Alcohol and drug use during sexual activity and compliance with safe sex guidelines for AIDS: the AIDS Behavioral Research Project. Health Educ Q 1986;13:359-371.
3. McCusker J, Westenhouse J, Stodard AM, Zapka JG, Zorn MW, Mayer KH. Use of drugs and alcohol by homosexually active men in relation to sexual practices. J Acquir Immune Defic Syndr 1990;3:729-736.
4. Robertson JA, Plant MA. Alcohol, sex, and risks of HIV infection. Drug Alcohol Depend 1988;22:75-78.
5. Hingson RW, Strunin L, Berlin BM, Heeren T. Beliefs about AIDS, use of alcohol and drugs, and unprotected sex among Massachusetts adolescents. Am J Public Health 1990;80:295-299.
6. National Institute of Alcohol Abuse and Alcoholism. Alcohol and AIDS. Alcohol Alert January 1992, No. 15.
7. Leigh BC, Stall R. Substance use and risky sexual behavior for exposure to HIV. Am Psychol 1993;48:1035-1045.
8. The Italian Seroconversion Study. Disease progression and early predictors of AIDS in HIV- 9. Lake-Baharr G, Rao RS. Alcohol and HIV disease progression in intravenous drug addicts. Presented at the Fifth International Conference on AIDS; Montreal, Canada; June 4-9, 1989.
10. Kaslow RA, Blackwelder WC, Ostrow DG, et al. No evidence for a role of alcohol or other psychoactive drugs in accelerating immunodeficiency in HIV-1 positive individuals: a report from the Multicenter AIDS Cohort Study. JAMA 1989;261:3424.
11. Bagasra O, Kajdacsy-Balla A, Lischner HW. Effects of alcohol ingestion on in vitro susceptibility of peripheral blood mononuclear cells to infection with HIV and of selected T-cell functions. Alcohol Clin Exp Res 1989;13:636-643.
12. Balla AK, Lischner HW, Pomerantz RJ, Bagasra O. Human studies on alcohol and susceptibility to HIV infection. Alcohol 1994;11:99-103.
13. Ronald PJM, Robertson JR, Elton R. Continued drug use and other cofactors for progression to AIDS among injecting drug users. AIDS 1994;8:339-343.
14. Meyerhoff DJ, McKay S, Sappey-Marinier D, et al. Effects of chronic alcohol abuse and HIV infection on brain phosphorus metabolites. Alcohol Clin Exp Res 1995;19:685-692.
15. Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with HIV, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med 1992;92:495-502.
16. Broers B, Morabia A, Hirschel B. A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med 1994;154:1121-1127.
17. Goldman L. HIV Disease: Medical Knowledge Self-Assessment Program. 10th ed. Philadelphia, Pa: American College of Physicians; 1994.
18. Centers for Disease Control and Prevention. HIV/AIDS Surv Rep 1994;6:10-13.
19. Scheidt DM, Windle M. Individual and situational markers of condom use and sex with nonprimary partners among alcoholic inpatients: findings from the AT RISK study. Health Psychol 1996;15:185-192.
20. Scheidt DM, Windle M. The Alcoholics in Treatment HIV Risk (AT RISK) Study: gender, ethnic, and geographic group comparisons. J Stud Alcohol 1995;56:300-308.
21. Avins AL, Woods WJ, Lindan CP, Hudes ES, Clark W, Hulley SB. HIV infection and risk behaviors among heterosexuals in alcohol treatment programs. JAMA 1994;271:515-518.
22. Fitterling JM, Matens PB, Scotti JR, Allen JS Jr. AIDS risk behaviors and knowledge among heterosexual alcoholics and non-injecting drug users. Addiction 1993;88:1257-1265.
23. Katz SM, Galanter M, Lifshutz H, Maslansky R. The impact on behavior of notifying methadone patients of their HIV serostatus. Am J Drug Alcohol Abuse 1995;21:37-45.
24. Leshner A. Understanding drug addiction: implications for treatment. Hosp Pract 1996;31:47-59.
25. Marlatt GA, Gordon JR, eds. Relapse Prevention: Maintenance Strategies in the Treatment of Addiction Behaviors. New York, NY: The Guilford Press; 1985.
26. Erikson PG, Riley DM, Cheung YW, O'Hare PA, eds. Harm Reduction: A New Direction for Drug Policies and Programs. Toronto, Canada: University of Toronto Press; 1996.
27. Marlatt GA, Tapert SF. Harm reduction: reducing the risks of addictive behaviors. In: Baer JS, Marlatt GA, McMahon R, eds. Addictive Behaviors Across the Lifespan. Newbury Park, Calif: Sage Publications; 1993:243-273.
28. Project MATCH Research Group. Matching alcoholism treatments to client heterogeneity: Project MATCH posttreatment drinking outcomes. J Stud Alcohol 1997;58:7-29.
29. Swanson J, Cooper A. The Complete Relapse Prevention Skills Program. Center City, Minn: Hazelden; 1994.
30. Swanson J, Cooper A. Relapse and HIV Risk. Center City, Minn: Hazelden; 1995.
31. Wexler H, Magura S, Josepher H, et al. ARRIVE: an AIDS education/ 32. Carpenter CJ, Fischl MA, Hammer JM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. JAMA 1996;276:146-154.
33. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996;276:105-110.
34. Lyketsos CG, McHugh PR, Hanson A, Treisman G, Fishman M. Screening for psychiatric morbidity in a medical outpatient clinic for HIV infection: the need for a psychiatric presence. Int J Psychiatry Med 1994;24:103-113.
35. Rollnick S, Bell A. Brief motivational interviewing for use by the nonspecialist. In: Miller WR, Rollnick S, eds. Motivational Interviewing. New York, NY: The Guilford Press; 1991.
36. Babor TF. Alcohol-related problems in a primary health care setting: a review of early intervention strategies. Br J Addict 1986;81:23-46.
37. Skinner HA, Holt S. Early intervention for alcohol problems. J R Coll Gen Pract 1983;33:787-791.
38. Babor TF, Grant M. From clinical research to secondary prevention: international collaboration in the development of the Alcohol Use Disorders Identification Test (AUDIT). Alcohol Health Res World 1989;13:371-374.
39. Miller W, Hester R. Treating the problem drinker: modern approaches. In: The Addictive Behaviors: Treatment of Alcoholism, Drug Abuse, Smoking, and Obesity. New York, NY: Pergamon Press; 1980.
This article was provided by International Association of Physicians in AIDS Care. It is a part of the publication Journal of the International Association of Physicians in AIDS Care.
|
|
|||||||||||||||||||||||||||||||||||||||||